BHC - Bausch Health Companies Inc.
| Previous Close | 28.40 |
| Open | 27.65 |
| Bid | 27.89 x 1100 |
| Ask | 27.92 x 800 |
| Day's Range | 27.42 - 28.01 |
| 52 Week Range | 18.72 - 31.97 |
| Volume | 477,384 |
| Avg. Volume | 3,819,483 |
| Market Cap | 9.875B |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 09, 2010 |
| 1y Target Est | 34.59 |
- Barrons.com
Disney Stock Looks Attractive for the Next 10 Years, Bill Priest Says
Barron’s Roundtable panelist William Priest says that by focusing on creative talent and shared infrastructure, Disney can make a meaningful transition.
- Zacks
Should Value Investors Pick Bausch Health (BHC) Stock Now?
Is Bausch Health (BHC) a great pick from the value investor's perspective right now? Read on to know more.
- CNW Group
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19
- PR Newswire
Bausch Health Publishes Company Update for the 38th Annual J.P. Morgan Healthcare Conference
Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") has published a brief company update presentation designed to complement remarks that will be provided by management during a fireside chat at 1:30 p.m. PT (4:30 p.m. ET) today during the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation provides an overview of the Company's recent performance and achievements, including updates on the Company's 2019 commitments and development programs, and offers insight into future goals and catalysts for 2020 and beyond.
- CNW Group
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO™ (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO™ (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)
- GuruFocus.com
What We Can Learn From Bill Ackman's Turnaround
The activist guru's recovery is a lesson for everyone Continue reading...
- CNW Group
Bausch + Lomb Launches Expanded Parameters for Biotrue® ONEday for Astigmatism Daily Disposable Contact Lenses
Bausch + Lomb Launches Expanded Parameters for Biotrue® ONEday for Astigmatism Daily Disposable Contact Lenses
- PR Newswire
Bausch Health To Participate At The 38th Annual J.P. Morgan Healthcare Conference
Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 13, 2019 at 1:30 p.m. PT (4:30 p.m. ET).
- Zacks
Aerie's (AERI) Application for Roclanda Accepted in Europe
European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
- Zacks
5 Reasons Why Ironwood Stock Should Be in Your Portfolio
We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.
- American City Business Journals
How another FDA approval strengthens a company's Triangle operations
Continuing its stretch of receiving FDA approvals, a global dermatology company's foothold in the Triangle looks even stronger heading into 2020.
- Insider Monkey
How Did Bausch Health Companies (BHC) Compare Against Top Hedge Fund Stocks in 2019?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before last year's Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the […]
- Zacks
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris
Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.
- CNW Group
Bausch Health Licenses Novaliq's NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
LAVAL, Quebec and HEIDELBERG , Germany , Dec. 20, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced today that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
- PR Newswire
Bausch Health Licenses Novaliq's NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced today that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
- PR Newswire
Bausch Health Announces Resolution Of BRYHALI® (Halobetasol Propionate) Lotion, 0.01%, Intellectual Property Litigation With Glenmark
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, have agreed to resolve the outstanding intellectual property litigation with Glenmark Pharmaceuticals, Ltd. (Glenmark), regarding BRYHALI® (halobetasol propionate) Lotion, 0.01%. The Company will grant Glenmark a non-exclusive license effective 2026 to its intellectual property relating to BRYHALI Lotion in the United States.
- CNW Group
Bausch + Lomb Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024%) Now Publicly Covered Under the Ontario Public Drug Benefit (ODB) Program
Bausch + Lomb Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024%) Now Publicly Covered Under the Ontario Public Drug Benefit (ODB) Program
- GuruFocus.com
Thinking About Capital Allocation
Managers who are outstanding capital allocators are vital to achieving long-term investment results Continue reading...
